Literature DB >> 17521369

The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response.

Antoine Minne1, Jamila Louahed, Sybille Mehauden, Benoît Baras, Jean-Christophe Renauld, Rita Vanbever.   

Abstract

Pulmonary vaccination is a promising immunization route. However, there still remains a crucial need to characterize the different parameters affecting the efficacy of inhaled vaccination. This study aimed at assessing the impact of antigen distribution within the respiratory tract on the immune response to a monovalent A/Panama/2007/99 H3N2 influenza split virus vaccine administered to BALB/c mice. Varying the administration technique allowed the targeting of the vaccine to different sites of the mouse respiratory tract, i.e. the nasal cavity, the upper or central airways, or the deep lung. This targeting was verified by using ovalbumin as a tracer compound. The immune responses generated following influenza vaccine administration to the different respiratory tract sites were compared to each other and to those elicited by intramuscular and peroral intragastric immunization. Delivery of the vaccine to the different respiratory regions generated systemic, local and cellular virus-specific immune responses, which increased with the depth of vaccine deposition, culminating in deep-lung vaccination. The latter induced virus-specific serum immunoglobulin G and neutralizing antibody titres as elevated as intramuscular vaccination, whereas the production of mucosal secretory immunoglobulin A was significantly superior in deep-lung-vaccinated animals. The analysis of cytokines secreted by mononuclear cells during an in vitro recall response indicated that deep-lung vaccination induced a local shift of the cellular immune response towards a T helper type 1 phenotype as compared to intramuscular vaccination. In conclusion, antigen distribution within the respiratory tract has a major effect on the immune response, with the deep lung as the best target for inhaled influenza vaccination.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17521369      PMCID: PMC2266027          DOI: 10.1111/j.1365-2567.2007.02641.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  46 in total

1.  Nasal mucociliary clearance as a factor in nasal drug delivery.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1998-01-05       Impact factor: 15.470

2.  Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules.

Authors:  Catherine Lombry; David A Edwards; Véronique Préat; Rita Vanbever
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-12-24       Impact factor: 5.464

3.  Mucociliary and long-term particle clearance in the airways of healthy nonsmoker subjects.

Authors:  Winfried Möller; Karl Häussinger; Renate Winkler-Heil; Willi Stahlhofen; Thomas Meyer; Werner Hofmann; Joachim Heyder
Journal:  J Appl Physiol (1985)       Date:  2004-09-03

Review 4.  Cytokines induce the development of functionally heterogeneous T helper cell subsets.

Authors:  A O'Garra
Journal:  Immunity       Date:  1998-03       Impact factor: 31.745

Review 5.  Vaccination by aerosols: modulation of clearance mechanisms in the lung.

Authors:  A Hensel; W Lubitz
Journal:  Behring Inst Mitt       Date:  1997-02

6.  Site of antigen delivery can influence T cell priming: pulmonary environment promotes preferential Th2-type differentiation.

Authors:  S L Constant; K S Lee; K Bottomly
Journal:  Eur J Immunol       Date:  2000-03       Impact factor: 5.532

7.  Local and systemic immune response in community-dwelling elderly after intranasal or intramuscular immunization with inactivated influenza vaccine.

Authors:  M Muszkat; A B Yehuda; M H Schein; Y Friedlander; P Naveh; E Greenbaum; M Schlesinger; R Levy; Z Zakay-Rones; G Friedman
Journal:  J Med Virol       Date:  2000-05       Impact factor: 2.327

Review 8.  Serious morbidity and mortality associated with influenza epidemics.

Authors:  W P Glezen
Journal:  Epidemiol Rev       Date:  1982       Impact factor: 6.222

9.  Clearance of different-sized proteins from the alveolar space in humans and rabbits.

Authors:  R H Hastings; M Grady; T Sakuma; M A Matthay
Journal:  J Appl Physiol (1985)       Date:  1992-10

Review 10.  Anatomical features of anti-viral immunity in the respiratory tract.

Authors:  David L Woodland; Troy D Randall
Journal:  Semin Immunol       Date:  2004-06       Impact factor: 11.130

View more
  20 in total

1.  A nonhuman primate toxicology and immunogenicity study evaluating aerosol delivery of AERAS-402/Ad35 vaccine: Evidence for transient t cell responses in peripheral blood and robust sustained responses in the lungs.

Authors:  David A Hokey; Robert Wachholder; Patricia A Darrah; Diane L Bolton; Dan H Barouch; Krystal Hill; Veerabadran Dheenadhayalan; Stephan Schwander; C Steven Godin; Macaya Douoguih; Maria Grazia Pau; Robert A Seder; Mario Roederer; Jerald C Sadoff; Donata Sizemore
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems.

Authors:  Susanne R Youngren-Ortiz; Nishant S Gandhi; Laura España-Serrano; Mahavir B Chougule
Journal:  Kona       Date:  2015-09-30       Impact factor: 2.897

3.  Immunomodulatory properties of subcellular fractions of a G+ bacterium, Bacillus firmus.

Authors:  Dana Cechova; Michaela Novakova; Karel Mikulik; Olga Novotna; Jaroslav Julak; Peter Zanvit; Ludmila Prokesova
Journal:  Folia Microbiol (Praha)       Date:  2012-08-09       Impact factor: 2.099

Review 4.  Microneedle and mucosal delivery of influenza vaccines.

Authors:  Sang-Moo Kang; Jae-Min Song; Yeu-Chun Kim
Journal:  Expert Rev Vaccines       Date:  2012-05       Impact factor: 5.217

5.  FcRn-Targeted Mucosal Vaccination against Influenza Virus Infection.

Authors:  Susan Park Ochsner; Weizhong Li; Arunraj Mekhemadhom Rajendrakumar; Senthilkumar Palaniyandi; Gyanada Acharya; Xiaoyang Liu; Gefei Wang; Florian Krammer; Meiqing Shi; Wenbin Tuo; C David Pauza; Xiaoping Zhu
Journal:  J Immunol       Date:  2021-08-11       Impact factor: 5.426

6.  Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice.

Authors:  Emily K Forbes; Clare Sander; Edward O Ronan; Helen McShane; Adrian V S Hill; Peter C L Beverley; Elma Z Tchilian
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

7.  Mucosal application of gp140 encoding DNA polyplexes to different tissues results in altered immunological outcomes in mice.

Authors:  Jamie F S Mann; Paul F McKay; Samantha Arokiasamy; Reeyeshkumar K Patel; John S Tregoning; Robin J Shattock
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

8.  Enhancement of the immunogenicity and protective efficacy of a mucosal influenza subunit vaccine by the saponin adjuvant GPI-0100.

Authors:  Heng Liu; Harshad P Patil; Jacqueline de Vries-Idema; Jan Wilschut; Anke Huckriede
Journal:  PLoS One       Date:  2012-12-17       Impact factor: 3.240

9.  Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice.

Authors:  Julie Todoroff; Muriel M Lemaire; Catherine Fillee; Fabienne Jurion; Jean-Christophe Renauld; Kris Huygen; Rita Vanbever
Journal:  PLoS One       Date:  2013-05-10       Impact factor: 3.240

10.  Evaluation of mucosal and systemic immune responses elicited by GPI-0100- adjuvanted influenza vaccine delivered by different immunization strategies.

Authors:  Heng Liu; Harshad P Patil; Jacqueline de Vries-Idema; Jan Wilschut; Anke Huckriede
Journal:  PLoS One       Date:  2013-07-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.